HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The benefits of platelet glycoprotein IIb/IIIa receptor inhibition during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: drug-specific or class effect?

AuthorsSorin J Brener
JournalJournal of the American College of Cardiology (J Am Coll Cardiol) Vol. 53 Issue 18 Pg. 1674-6 (May 05 2009) ISSN: 1558-3597 [Electronic] United States
PMID19406343 (Publication Type: Editorial, Comment)
Chemical References
  • Antibodies, Monoclonal
  • Fibrinolytic Agents
  • Immunoglobulin Fab Fragments
  • Peptides
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Tyrosine
  • Tirofiban
  • Eptifibatide
  • Abciximab
Topics
  • Abciximab
  • Angioplasty, Balloon, Coronary
  • Antibodies, Monoclonal (therapeutic use)
  • Eptifibatide
  • Fibrinolytic Agents (therapeutic use)
  • Humans
  • Immunoglobulin Fab Fragments (therapeutic use)
  • Myocardial Infarction (drug therapy, therapy)
  • Peptides (therapeutic use)
  • Platelet Aggregation Inhibitors (therapeutic use)
  • Platelet Glycoprotein GPIIb-IIIa Complex (antagonists & inhibitors)
  • Tirofiban
  • Tyrosine (analogs & derivatives, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: